Male Hypogonadism, Active Fertility Plans: The Case Against Exogenous Testosterone
A single patient, referred to urology after a fertility workup flagged the testosterone gel his own doctor started. The disagreement isn't about whether he's hypogonadal — it's about which of three unproven alternatives to exogenous testosterone actually protects the fertility he still has.
Desmond R., a 33-year-old woodworking and shop teacher, has been trying to conceive with his wife for fourteen months, a stretch long enough that her reproductive endocrinologist ordered a full workup on both of them. His came back with something nobody expected to matter: a testosterone gel his own primary care physician had started two months earlier for fatigue and a flagging libido, prescribed before anyone had asked whether he and his wife were actively trying. His total testosterone on two morning draws averaged 218 ng/dL, comfortably below the usual 300 ng/dL treatment threshold — but his LH and FSH were both low-normal rather than elevated, the pattern of secondary rather than primary hypogonadism, meaning the defect sits above the testes themselves and the axis is still there to be stimulated rather than simply replaced.
That distinction is what makes today’s decision urgent rather than routine. His semen analysis, drawn before the gel had time to do much damage, still showed a concentration of 38 million/mL with normal motility and morphology — comfortably above the WHO reference thresholds for male fertility, a baseline worth protecting rather than one to gamble against. Exogenous testosterone suppresses the same intratesticular signal his LH and FSH are already only weakly producing, driving intratesticular testosterone down even as serum levels rise, which is exactly the mechanism that can turn a fertile man azoospermic within months. The AUA/ASRM male infertility guideline states the risk plainly as a clinical principle: a man interested in current or future fertility should not be prescribed exogenous testosterone. What the guideline does not do is name which of the alternatives — clomiphene, hCG, or an aromatase inhibitor — actually belongs in his hand today, since none has ever been tested against the others in a trial built to answer that question, and each works through a genuinely different point in the same axis.
In the urology clinic, choosing what replaces the gel
Stop the gel today and start clomiphene citrate, 25 mg every other day. He still has an intact axis — low-normal gonadotropins, not undetectable ones — which is exactly the population clomiphene is meant for: it blocks estrogen’s negative feedback at the hypothalamus, which should lift his own LH and FSH rather than replacing them from outside.
If his LH and FSH had come back frankly suppressed rather than low-normal, I’d be less confident an oral agent alone gets there — but that isn’t what his labs show.
I hear that, and I'll own that I started the gel before I knew fertility was the priority. But clomiphene is off-label for this indication with no dedicated trial behind it, and neither is hCG, and neither is anastrozole — we're choosing among three unproven options, not one proven one. Given the fourteen months already gone by, I'd rather start hCG alongside the clomiphene now than wait to see if one agent alone is enough.
Calling clomiphene the obvious first choice understates how thin that evidence base actually is — it's routine practice, not a studied one.
Both of you are right that none of these three has been compared head-to-head, and I don't think that gap resolves today — but starting two agents at once removes our ability to tell, three months from now, which one actually moved his numbers if something needs adjusting. Clomiphene alone is also the lower-burden start: a pill rather than injections, and hCG remains genuinely available to add if his recheck at twelve weeks doesn't show the response we want.
The AUA testosterone-deficiency guideline is worth quoting exactly here, because it cuts against rushing: roughly two-thirds of men recovered sperm in the ejaculate within six months of stopping exogenous testosterone, while one in ten took until the second year. I’d flag what that figure rests on, though — it comes from male contraceptive studies in fertile volunteers, and the same guideline says plainly that recovery is not well established in infertile men, which is the group he’s actually in. Fourteen months already elapsed doesn't mean fourteen more are coming — it means we watch the axis respond on its own timeline, not force two drugs onto a problem that may correct with one.
Agreed: the testosterone gel stops today, clomiphene citrate 25 mg every other day starts in its place, and testosterone, LH, FSH, and a repeat semen analysis are rechecked in twelve weeks rather than sooner — long enough for a real signal, short enough not to waste more of the fertility window than necessary.
Not agreed: whether hCG should have started alongside clomiphene today rather than waiting for the recheck. The primary care physician would rather move on two fronts given how much time has already passed; the urologist and pharmacologist preferred an interpretable single-agent trial first, with hCG confirmed as the next step rather than a hedge added out of impatience.